Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals-Reference-Cited by-同舟云学术

Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals

Published:2024-03 Issue:3 Volume:24 Page:e147-e148
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Kosugi Yusuke,Kaku Yu,Hinay Alfredo A,Guo Ziyi,Uriu Keiya,Kihara Minoru,Saito Fumitake,Uwamino Yoshifumi,Kuramochi Jin,Shirakawa Kotaro,Takaori-Kondo Akifumi,Sato Kei

Funder

JST

Publisher

Elsevier BV

Reference3 articles.

1. Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant;Uriu;Lancet Infect Dis,2023

2. Virological characteristics of the SARS-CoV-2 omicron HK.3 variant harboring the “FLip” substitution;Kosugi;BioRxiv,2023

3. Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5;Kaku;Lancet Infect Dis,2023

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Virological characteristics of the SARS-CoV-2 KP.3.1.1 variant;The Lancet Infectious Diseases;2024-08

2. Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster;Cell Reports Medicine;2024-08

3. Virological characteristics of the SARS-CoV-2 KP.3.1.1 variant;2024-07-17

4. Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages;2024-05-29

5. Antigenic cartography using hamster sera identifies SARS-CoV-2 JN.1 evasion seen in human XBB.1.5 booster sera;2024-04-06